This is how AI will shape drug discovery
AI software is expanding the universe of screenable compounds and will deliver higher hit rates as compounds move through the pharma value chain.
B Capital Group Partner: Pharma value chain will be area of interest for investors in 2018
B Capital Group Partner Gavin Teo said tax reform and a more liberal FDA are helping to make technologies supporting drug research and development more attractive to investors.
presented by
Esperion Sets Its Sights on New Areas While Maintaining Commitment to Cardiovascular Health
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases